Publications
31
Citations
258
Est. group size
~11
Recurring co-author estimate
Active years
13
Publishing since 2012
Michael Ozga's research focuses on blood cancers and bone marrow transplantation, particularly stem cell transplants used to treat conditions like myelofibrosis (a disorder where bone marrow is replaced by scar tissue) and T-cell lymphoma (a cancer of white blood cells). Much of the work involves large, multi-institutional studies comparing transplant approaches, including using partially matched ('haploidentical') donors combined with a chemotherapy drug (cyclophosphamide) given after transplant to reduce complications. This research is intended to inform treatment strategies for patients with rare and difficult-to-treat blood cancers.
Publication output rose sharply around 2020 and has since declined to a lower, fluctuating level through 2023-2024.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
Leukemia · 2021
- Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis
Blood · 2020
- Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience
Blood · 2020
- Blood×9
- Clinical Lymphoma Myeloma & Leukemia×3
- Leukemia×2
- American Journal of Hematology×2
- Biology of Blood and Marrow Transplantation×2
- Kristin L Koenig
Medicine · The Ohio State University
- Bei Liu
Medicine · The Ohio State University
- Nicole Abbott
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
- Hamid Sayar
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile